AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02510495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: 300 group
Description: A small sphincterotomy (EST) was performed prior to the EPBD, the length of a small sphincterotomy was considered as no larger than the range which from the orifice to the top one-third of the papilla. a CRE balloon (diameter 8, 9, 10, 11, 12, 13.5, 15; Boston Scientific) was chosen according to the diameter of bile duct. It was placed across the papilla orifice and then gradually filled with diluted contrast in 15 seconds. When the waist disappeared, the balloon was inflated till 300 seconds prior deflated. The stones were then retrieved by a basket or retrieval balloon. Mechanical lithotripsy was used if necessary.
Study NCT00529399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum
Description: Participants will receive 3 injections of 20 micrograms GAD-Alum subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
Study NCT00529399 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GAD-Alum and Aluminum hydroxide
Description: Participants will receive 3 injections subcutaneously. The first two will contain 20 micrograms GAD-Alum vaccine and are given 4 weeks apart. The third injection will be Aluminum hydroxide alone and will be given 8 weeks after the second injection.
Study NCT00529399 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Aluminum hydroxide
Description: Participants will receive 3 injections of Aluminum hydroxide alone, subcutaneously. The first two injections are given 4 weeks apart and the second and third are given 8 weeks apart.
Study NCT03347968 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MEDI0382
Description: All participants will receive MEDI0382
Study NCT03347968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: All participants will receive Warfarin
Study NCT03347968 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Esmolol
Description: All participants will receive Esmolol
Study NCT04298593 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Cardiostat
Description: This is a prospective observational study including patients accepted by the heart team for a TAVI procedure. There will be no restriction regarding the type of valve and approach used for the TAVI procedure. Following the TAVI procedure, the patients will be under telemetry until hospital discharge and, at hospital discharge, they will be monitorized up to 4 more weeks using the CardioSTAT® device.
Study NCT00909012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: high oleic sunflower oil
Description: placebo, which does not provide DHA
Study NCT00909012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 20 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
Study NCT00909012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 40 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
Study NCT00909012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 80 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
Study NCT00909012 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: microalgal oil
Description: the supplement provides 130 mg DHA per capsule (1 or 2 are consumed per day, depending on body weight)
Study NCT01027546 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic Acid
Description: Administer 15 mg/kg body weight of tranexamic Acid mixed in 100 mL saline intravenously over 15 min before the skin incision
Study NCT03565887 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVL-1201
Description: RVL-1201 ophthalmic solution 0.1%
Study NCT03565887 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle ophthalmic solution
Description: Vehicle placebo ophthalmic solution
Study NCT03453268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: STEP DOWN strategy
Description: reduction of the number of antihypertensive medication according to:~* the systolic blood pressure levels,~* co-morbidities
Study NCT03453268 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Control
Description: usual treatment
Study NCT03173040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NiuBangZi pill or NiuBangZi pill placebo
Description: For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
Study NCT03173040 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: NiuBangZi pill or NiuBangZi pill placebo
Description: For the treatment group (NiuBangZi pill group), patients will be instructed to dissolve NiuBangZi pill (4 g) in 200 mL hot water and take the solution orally twice a day for 3 months. While patients in the placebo group will take NiuBangZi pill placebo as the same way. Besides that, both groups will also administrate MTX (5 mg per week) in addition, and glucocorticoid (less than 5mg a day) if necessary, but any other drugs especially herbs not permit.
Study NCT05599828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 510
Description: Oral Tablet
Study NCT05599828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Omeprazole
Description: Capsule
Study NCT05599828 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Famotidine
Description: Tablet
Study NCT03244020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspirin 325mg
Description: Aspirin 325 mg by mouth once daily
Study NCT03244020 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin 40Mg/0.4mL Prefilled Syringe
Description: Enoxaparin 40 mg subcutaneous injection once daily
Study NCT04088838 — intervention group
Intervention type: OTHER
Intervention: Pain tracking app
Description: In this study no clinical interventions are made. Patients scheduled for surgery will be treated according to the standard of care. All patients enrolled will have an application installed to track their pain symptoms through short daily and weekly questionnaires.
Study NCT00605280 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Standard of Care
Description: Clinicians decision to use optional laser therapy.
Study NCT00605280 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Macugen
Description: Intravitreal injection of Macugen 0.3mg/90ul every 6 weeks up to 2 years.
Study NCT01737580 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: resiquimod
Study NCT01737580 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo gel
Study NCT03712644 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFR-guided coronary revascularization
Description: Stenoses in range of 50-90% diameter stenosis in major coronary arteries will be assessed by FFR, and revascularized if FFR equal to or lower than 0.80. Lesions above 90% diameter stenosis in will be revascularized without further assessment.
Study NCT02660034 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Study NCT02660034 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pamiparib
Study NCT01212952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: pomalidomide
Description: Given orally
Study NCT01212952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib
Description: Given IV
Study NCT01212952 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: Given orally
Study NCT01212952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Optional correlative studies
Study NCT01212952 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: gene expression analysis
Description: Optional correlative studies
Study NCT02234869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Interferon Beta
Description: Subcutaneous injection
Study NCT02234869 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIIB017 (Peginterferon beta-1a)
Description: Single-use, disposable, prefilled pen for subcutaneous injection
Study NCT02234869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB017 (Peginterferon beta-1a)
Description: Single-use, disposable, prefilled pen for subcutaneous injection
Study NCT03609762 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: EQ-5D-5L HRQOL results be available to the attending doctor
Description: all subjects attending the intervention clinics will complete the electronic EQ-5D-5L before seeing the doctor during each follow-up visit for the musculoskeletal problem, a print out of the longitudinal EQ-5D-5L data (Table 1) since recruitment will be given to the patients to show to the attending doctors during the consultation. The doctors will provide the management based on the usual clinical information and the additional EQ-5D-5L HRQOL results. The doctor will complete the clinician-reported follow-up clinical data form (CRF) of each eligible patient at the end of the consultation.
Study NCT02053818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Remifentanil
Description: Randomization to receive Remifentanil (ultrashort acting opioid) as basic opioid in anaesthesia
Study NCT02008474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + incentives for behavior 3 months
Description: Participants will receive monetary incentives for submitting their behavior change information into a study website
Study NCT02008474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + incentives for weight loss at month 3
Description: Participants will receive an incentive for meeting their weight loss goal at month 3.
Study NCT02053818 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sufentanil
Description: Randomization to receive Sufentanil (medium/long acting opioid) as basic opioid in anaesthesia
Study NCT02008474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + Incentives for behavior 12 months
Description: Participants will receive incentives for submitting behavior change information over the course of 12 months.
Study NCT00905918 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: vitamin E
Description: Given orally
Study NCT00905918 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: All patients undergo biomarker analyses
Study NCT03282318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP6294
Description: Participants will receive 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Study NCT02008474 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Online weight loss + Incentives for weight loss 12 months
Description: Participants will be receive monetary incentives for reaching their weight loss goal at months 3 and 12.
Study NCT04804423 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 38% Silver Fluoride and Potassium Iodide solution (generic name; Riva Star®)
Description: 38% silver fluoride will be applied to the surface of the isolated hypersensitive carious lesion followed by application of potassium iodide solution and according to manufacturer's instructions.
Study NCT04804423 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sodium fluoride varnish (generic name; Duraphat®)
Description: 22,600 ppm sodium fluoride varnish will be applied on the surface of the affected hypersensitive active carious lesions.
Study NCT00568230 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PTMA (Percutaneous Transvenous Mitral Annuloplasty) Implant
Description: Percutaneous access from right or left subclavian vein with placement of assessment and placement of PTMA Implant into the coronary sinus, great cardiac vein. Device remains accessible from a subclavicular pocket.
Study NCT03779217 — intervention group
Intervention type: OTHER
Intervention: screening mammography
Description: As indicated by international guidelines authors will perform screening mammography in all asymptomatic women.
Study NCT03282318 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Participants will receive placebo to match 320 mg ASP6294 subcutaneous injection at 4-week intervals at baseline (Day 1/Week 0), Week 4 and Week 8.
Study NCT03779217 — intervention group
Intervention type: PROCEDURE
Intervention: mastoplasty and breast fat excission
Description: As indicated by guidelines, and in accordance to the breast surgery reduction criteria, the authors will practice a surgical intervention of mastoplasty. During the mastoplasty, authors will remove the breast fat tissue.
Study NCT02936193 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Pylorus preservation
Description: Patients undergo Laparoscopic Gastrectomy featuring pylorus-preservation
Study NCT02936193 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Distal gastrectomy
Description: Patients undergo laparoscopic gastrectomy in distal gastric resection with D2 lymphadenectomy
Study NCT03192202 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AFM13
Description: AFM13 is a recombinant antibody construct against human CD30 and CD16A. It will be given to patients intravenously at the dose and schedule applicable to the cohort the patient was enrolled in specified in the various arms listed.
Study NCT02155621 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Genome sequencing
Description: Subjects will have their cancers biopsied and blood samples taken; both will undergo genomic sequencing and analysis
Study NCT02218047 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated-Proline-interferon alpha-2b
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Study NCT02218047 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Best available therapy (BAT)
Description: Best available therapy as selected by the investigator
Study NCT02530125 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02530125 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pidilizumab
Description: Given IV
Study NCT02162251 — intervention group
Intervention type: DRUG
Intervention: Donepezil Hydrochloride
Description: Initial dose of 3 mg orally once daily. After 1-2 weeks, dosage increased to 5 mg orally once daily. After 4 or more weeks, dosage increased to 10 mg orally once daily for patients with severe dementia of Alzheimer's type. Dose reduced appropriately according to patient's symptoms.
Study NCT04402762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ovine Enoxaparin
Description: The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
Study NCT04402762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ovine Enoxaparin
Description: The test drug is ovine enoxaparin sodium 60 mg (0.6 mL taken from 1.0 mL vial containing 100 mg = 10,000 IU anti-FXa), from Metiska Farma.
Study NCT04402762 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin Prefilled Syringe [Lovenox]
Description: The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
Study NCT04402762 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Enoxaparin Prefilled Syringe [Lovenox]
Description: The reference drug is enoxaparin sodium 60 mg (Lovenox® 0.6 mL prefilled syringe containing 60 mg = 6,000 IU anti-FXa) from Sanofi, France.
Study NCT03635515 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Gentlewave
Description: The Gentlewave system from Sonendo is a FDA cleared root canal irrigation device that uses broad spectrum acoustic energy, internally degassed distilled water, 3% NaOCl, and 8% EDTA to allow for a more thorough cleaning within the tooth. The fluids work to remove necrotic tissue, debris, biofilm, and bacteria while leaving dentin intact and preserving tooth structure. The Gentlewave irrigation replaces the NaOCl ultrasonic activation and EDTA steps of the standard endodontic protocol. Use of the Gentlewave system is contraindicated in teeth with immature apices, teeth with insufficient coronal structure, and teeth with root apices extending into the maxillary sinus.
Study NCT03635515 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Standard Endodontic Protocol
Description: The tooth will be sufficiently anesthetized with local anesthetic. The tooth will be rubber dam isolated. The pulp chamber will be accessed removing all caries, defective restorations, and defective crowns. EAL and radiographs will be used to determine the working length of each canal, all canals will be cleaned and shaped using rotary files to at least a size 25.04 canal size to within 0.5 to 1 mm of the apical terminus. Between each file 5.25% NaOCl will be used to disinfect and clear the canals of debris. A final passive ultrasonic activation of NaOCl will be done for 30 seconds per canal. Each canal will then soak in 17% EDTA for 1 minute, rinsed in 5.25% NaOCl, and finally undergo a final rinse of 95% ethanol. Canals will be obturated with root canal sealer and gutta-percha.
Study NCT01742988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fimepinostat
Study NCT01742988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Study NCT01742988 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: venetoclax
Study NCT03782012 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Supported
Description: Visual organization of knowledge base items plus discourse-based discussion supporting knowledge availability and accessibility
Study NCT06315595 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-interventional study
Study NCT04197869 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Polyethylene Glycol Powder
Description: Polyethylene Glycol 3350 17g should be mixed in 8 ounces of fluid for administration. Polyethylene glycol is a high molecular weight, water soluble polymer which can form hydrogen bonds with water molecules. It is an osmotic laxative solution which stimulates bowel movements by increasing the amount of water absorbed in the GI tract. It decreases feces consistency and increases their volume by promoting peristalsis and evacuation. The side effects of polyethylene glycol are bloating, gas or diarrhea. The half-life of polyethylene glycol is 4-6 hours and after 18 hours the concentration declines to non-quantifiable levels.
Study NCT03436394 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Evobrutinib
Description: Subjects will be administered a single oral dose of evobrutinib under fasting conditions.
Study NCT01763944 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Low carbohydrate diet
Description: The Low carbohydrate diet intervention recommends patients to limit carbohydrate intake to less than 20 gram per day.
Study NCT04408573 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Cycling deep brain stimulation
Description: Deep Brain Stimulation applied in cycling - periods of stimulation ON intercalated with periods of stimulation OFF
Study NCT00617344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD Dengue Vaccine , 5555 formulation
Description: A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively.
Study NCT00617344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD Dengue Vaccine , 5553 formulation
Description: A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
Study NCT00617344 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Tetravalent CYD Dengue Vaccine, 4444 formulation
Description: A 0.5 mL dose, Subcutaneous at 0, 6, and 12 months, respectively
Study NCT03364127 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Active Acupuncture
Description: Active Acupuncture two times per week for 5 weeks
Study NCT03364127 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Acupuncture
Description: Placebo Acupuncture two times per week for 5 weeks
Study NCT02696148 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: liraglutide
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study NCT02696148 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: For subcutaneous (s.c., under the skin) injection once daily.
Study NCT05071157 — intervention group
Intervention type: BEHAVIORAL
Intervention: echocardiography
Description: * speckle tracking echocardiography~* evaluation of cardiac variability by recording heart rate as several hours (POLAR watch)~* bioimpedance~* blood test for biological assays (metabolomic analysis)
Study NCT01846637 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic sleeve gastrectomy
Study NCT01846637 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: laparoscopic sleeve gastrectomy